drugset / Trial / NCT03377595

Post C-Section Pain Control Using EXPAREL

NCT03377595 ↗

Phase 4 Withdrawn University of Minnesota
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluating the safety and efficacy of EXPAREL (Liposomal Bupivacaine ) for pain control in patients undergoing scheduled cesarean section by giving it either as infiltration in Transversus Abdominis Plane after finishing the procedure or through wound infiltration into the fascia prior to closure of skin

Timeline

Start
2019-07-02
Primary completion
2019-08-30
Completion
2019-09-01

Outcome

Outcome not reported

Stopped: “Lack of resources, no data collected”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 266 mg Other

Indications